Protection by endogenous FGF-2 against isoproterenol-induced cardiac dysfunction is attenuated by cyclosporine A

[1]  E. Kardami,et al.  A single bout of exercise promotes sustained left ventricular function improvement after isoproterenol-induced injury in mice , 2011, The Journal of Physiological Sciences.

[2]  P. Pasdois,et al.  The role of the mitochondrial permeability transition pore in heart disease. , 2009, Biochimica et biophysica acta.

[3]  Zhi-Sheng Jiang,et al.  High molecular weight FGF-2 promotes postconditioning-like cardioprotection linked to activation of protein kinase C isoforms, as well as Akt and p70 S6 kinases. [corrected]. , 2009, Canadian journal of physiology and pharmacology.

[4]  M. Rossi,et al.  Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury , 2008, International journal of experimental pathology.

[5]  Ru Zhou,et al.  Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. , 2008, European journal of pharmacology.

[6]  T. Pozzan,et al.  Cardiac cell hypertrophy in vitro: role of calcineurin/NFAT as Ca2+ signal integrators. , 2008, Annals of the New York Academy of Sciences.

[7]  E. Feigl,et al.  Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. , 2007, The American journal of pathology.

[8]  E. Kardami,et al.  Fibroblast growth factor-2 and cardioprotection , 2007, Heart Failure Reviews.

[9]  M. Jeyaraman,et al.  High- but not low-molecular weight FGF-2 causes cardiac hypertrophy in vivo; possible involvement of cardiotrophin-1. , 2007, Journal of molecular and cellular cardiology.

[10]  X. Bigard,et al.  Cyclosporin A inhibits hypoxia-induced pulmonary hypertension and right ventricle hypertrophy. , 2006, American journal of respiratory and critical care medicine.

[11]  A. Weyman,et al.  Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. , 2006, European heart journal.

[12]  Zhi-Sheng Jiang,et al.  Administration of FGF-2 to the Heart Stimulates Connexin-43 Phosphorylation at Protein Kinase C Target Sites , 2006, Cell communication & adhesion.

[13]  Fumito Ichinose,et al.  Quantitative Assessment of Regional Myocardial Function in Mice by Tissue Doppler Imaging: Comparison With Hemodynamics and Sonomicrometry , 2005, Circulation.

[14]  E. Kardami,et al.  Basic fibroblast growth factor is cardioprotective in ischemia-reperfusion injury , 1995, Molecular and Cellular Biochemistry.

[15]  E. Kardami,et al.  Beyond angiogenesis: the cardioprotective potential of fibroblast growth factor-2. , 2004, Canadian journal of physiology and pharmacology.

[16]  F. Lallemand,et al.  Tissue Doppler imaging detects early asymptomatic myocardial abnormalities in a dog model of Duchenne's cardiomyopathy. , 2004, European heart journal.

[17]  E. Kardami,et al.  Transcriptional regulation of FGF-2 gene expression in cardiac myocytes. , 2004, Cardiovascular research.

[18]  Zhi-Sheng Jiang,et al.  Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion. , 2004, Cardiovascular research.

[19]  T. Doetschman,et al.  Cardiac-Specific Overexpression of Fibroblast Growth Factor-2 Protects Against Myocardial Dysfunction and Infarction in a Murine Model of Low-Flow Ischemia , 2003, Circulation.

[20]  E. Kardami,et al.  Biological activities of fibroblast growth factor-2 in the adult myocardium. , 2003, Cardiovascular research.

[21]  B. Doble,et al.  *These authors contributed equally to this paper Correspondence to: , 2022 .

[22]  E. Kardami,et al.  Exacerbation of myocardial injury in transgenic mice overexpressing FGF-2 is T cell dependent. , 2002, American journal of physiology. Heart and circulatory physiology.

[23]  R. Fandrich,et al.  Overexpression of FGF-2 increases cardiac myocyte viability after injury in isolated mouse hearts. , 2001, American journal of physiology. Heart and circulatory physiology.

[24]  S. Pawlowski,et al.  Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. , 1999, The Journal of clinical investigation.

[25]  B. Doble,et al.  FGF-2-induced negative inotropism and cardioprotection are inhibited by chelerythrine: involvement of sarcolemmal calcium-independent protein kinase C. , 1998, Journal of molecular and cellular cardiology.

[26]  H. Schunkert,et al.  Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. , 1998, Cardiovascular research.

[27]  D. Kaye,et al.  Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. , 1996, The Journal of clinical investigation.

[28]  H. Chiao,et al.  Contraction-induced cell wounding and release of fibroblast growth factor in heart. , 1995, Circulation research.

[29]  M. Pfeffer,et al.  Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. , 1994, Circulation research.

[30]  A. Hess.  Mechanisms of action of cyclosporine: considerations for the treatment of autoimmune diseases. , 1993, Clinical immunology and immunopathology.

[31]  J. Bluestone,et al.  Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. , 1990, Transplantation.

[32]  G. Rona,et al.  An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. , 1959, A.M.A. archives of pathology.